Human Translational Core

人类翻译核心

• 批准号: 10617218
• 负责人: ROHIT LOOMBA
• 金额: $ 26.9万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10617218
• 关键词: Achievement; Address; Animal Model; Animals; Biological Markers; Biological Specimen Banks; Biometry; California; Cell Culture Techniques; Clinical; Collection; Complement; Computerized Medical Record; Consultations; Coupled; Data Analyses; Data Management Resources; Diagnosis; Digestive System Disorders; Disease; Endoscopic Biopsy; Face; Feces; Gastroenterology; Gastrointestinal Diseases; Human; In Vitro; Inflammation; Inflammatory Bowel Diseases; Knowledge; Leadership; Link; Liver; Liver diseases; Metadata; Needle biopsy procedure; Online Systems; Outcome; Pathogenesis; Pathologic; Patients; Peripheral Blood Mononuclear Cell; Phenotype; Plasma; Pre-Clinical Model; Process; Research; Research Design; Research Personnel; Sample Size; Sampling; Serum; Services; System; Testing; Tissue Banks; Tissue Sample; Tissues; Translational Research; Universities; Upper digestive tract structure; Whole Blood; animal data; bench-to-bedside translation; biobank; chronic liver disease; clinical phenotype; cohort; cost effective; experience; functional genomics; gastrointestinal; human disease; human study; human tissue; innovation; liver biopsy; member; microbiome research; non-alcoholic fatty liver disease; phenotypic data; pre-clinical; sample collection; training opportunity; translational scientist; translational study

Summary The objective of the Human Translational Core is to facilitate bench-to-bedside translational studies by providing members of the San Diego Digestive Diseases Research Center ready access to human biospecimens of well-characterized cohorts of patients with digestive diseases. Moreover, The Core will provide clinical expertise for examining paradigms that emerge from basic studies conducted in animals and in vitro and relating them to clinical phenotypes seen in patients with digestive diseases. The Core will be led by highly accomplished clinical and translational researchers from the University of California, San Diego (UCSD) Division of Gastroenterology, with Dr. Rohit Loomba as Director, Dr. William Sandborn as Co-Director, and Dr. Sheila Crowe as Co-Investigator. Drs. Loomba and Sandborn have already established modest biorepositories in the Nonalcoholic Fatty Liver Disease (NAFLD) Center and Inflammatory Bowel Disease (IBD) Center, respectively. The proposed Core will build on these achievements and markedly expand and streamline the repository of biospecimens from well-characterized digestive disease patients as well as appropriate controls. Established strengths of this Core include the outstanding track record of the Core leadership in translational research related to inflammation in gastrointestinal and liver diseases; their experience in detailed phenotyping of patients with digestive diseases; access to existing and well-characterized cohorts of patients with specific digestive diseases; access to a biorepository of existing human biospecimens; synergistic interactions and the availability of state- of-the-art data management resources; and strong pathological and biostatistical expertise. This Core will interact with and complement the Preclinical Models and Microbiomics and Functional Genomics Cores by facilitating research to relate biomarkers and preclinical data from animal models to specific outcomes in patients with digestive diseases. The Human Translational Core has the following Aims: 1. To collect, process and annotate human tissue samples, including liver biopsies, endoscopic gastrointestinal tissues, whole blood, plasma, serum, peripheral blood mononuclear cell (PBMC), and stool; 2. To provide human biospecimens coupled with patient metadata to Center investigators; 3. To offer clinical, biostatistical and pathological consultation services, as well as training opportunities. Thus, this Core will benefit the Center members by providing reliable, cost-effective services for enhancing the scope and innovation of their research and its relevance to human diseases of the digestive tract.

概括 人类翻译核心的目的是通过 为圣地亚哥消化疾病的成员提供研究中心准备与人类的接触 良好特征的消化疾病患者的生物测量。而且，核心将提供 研究从动物，体外和 将它们与消化疾病患者中观察到的临床表型有关。核心将由高度领导 加州大学圣地亚哥分校的临床和转化研究人员有成熟的临床和翻译研究人员 Rohit Loomba博士担任胃肠病学，担任董事William Sandborn博士担任联合主任 克劳（Crowe）作为共同投资者。博士。 Loomba和Sandborn已经在 非酒精性脂肪肝病（NAFLD）中心和炎症性肠病（IBD）中心。 拟议的核心将基于这些成就，并明显扩展和简化 来自特征良好的消化系统疾病患者以及适当对照的生物测量。已确立的 该核心的优势包括与翻译研究相关的核心领导力的杰出记录 胃肠道和肝病的炎症；他们在患者的详细表型中经验 消化疾病；访问特定消化疾病的患者现有和良好的人群； 获得现有人类生物测量的生物验证；协同互动以及国家的可用性 艺术数据管理资源；以及强大的病理和生物统计专业知识。这个核心将 与临床前模型，微生物组学和功能基因组学核心相互作用并补充。 促进研究将生物标志物和临床前数据从动物模型与患者的特定结果相关联 患有消化系统疾病。人的翻译核心具有以下目的：1。收集，处理和 注释人体组织样品，包括肝活检，内镜胃肠道组织，全血， 血浆，血清，外周血单核细胞（PBMC）和粪便； 2。提供人类的生物测量 再加上患者元数据到中心调查人员； 3。提供临床，生物统计和病理 咨询服务以及培训机会。因此，该核心将受益于中心成员 提供可靠，具有成本效益的服务，以增强其研究范围和创新 与消化道的人类疾病有关。